Preoperative Magnetic Resonance (MR) Imaging of Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01347320
Recruitment Status : Completed
First Posted : May 4, 2011
Last Update Posted : December 30, 2013
Information provided by (Responsible Party):
Erik Rud, Oslo University Hospital

Brief Summary:

The investigators want to evaluate if preoperative MRI improves the surgical results, especially in respect to surgical margins. The impact on the surgical procedure will be evaluated.

In addition the investigators will examine the accuracy of tumor detection, localization and staging.

Condition or disease Intervention/treatment Phase
Prostate Cancer Other: Preoperative MRI Not Applicable

Detailed Description:


During the last two decades, Magnetic Resonance Imaging (MRI) of the prostate has evolved to become a promising tool in preoperative evaluation of prostate cancer. Several studies have evaluated the radiological and histopathological correlation. However, the sensitivity and specificity in regard to staging have shown wide ranges and poor reproducibility. These discrepancies can be explained by difference in patient selection, MRI methods, and criteria used for diagnosis. More studies are therefore needed to evaluate the clinical impact of preoperative MRI in patients with prostate cancer.

Aims of the study:

To evaluate 1) detection rate of tumor 1-3 (tumor 1 = index tumor), size of tumor 1-3, possible extraprostatic extension and predict presence of Gleason grade 4 and 5 tumor, 2) the influence of preoperative MRI on the surgical decision process with respect to the operative procedure for removal of the gland and pelvic lymph node dissection, and 3) the impact of preoperative MRI on the rate of positive surgical margins and functional results.

Material and method:

A prospective study including 400 consecutive patients referred to robot assisted laparoscopic prostatectomy randomised to preoperative MRI (intervention group) and no MRI (control group). The prostatectomy specimens will be histopathologically examined, and TNM classification will be performed according to 2002 AJCC standard.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 400 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Clinical Impact of MR Imaging in Patients With Prostate Cancer
Study Start Date : November 2009
Actual Primary Completion Date : July 2012
Actual Study Completion Date : July 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer
U.S. FDA Resources

Arm Intervention/treatment
No Intervention: No preoperative MRI
control arm of the study
Active Comparator: MRI group
preoperative MRI
Other: Preoperative MRI
Preoperative staging

Primary Outcome Measures :
  1. Surgical margins [ Time Frame: 30 days ]
    The surgical margins are assessed by evaluating the pathological specimen

Secondary Outcome Measures :
  1. Surgical decision process [ Time Frame: 30 days ]
    Evaluated using questionaire

  2. Preoperative TNM classification [ Time Frame: 1-4 weeks ]
    Based upon preoperative MRI

  3. Detection of Gleason grade 4 and 5 [ Time Frame: 30 days ]
  4. Functional outcome [ Time Frame: 1 year after prostatectomy ]
    Evaluate the functional outcome in respect to erectile dysfunction.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion criteria

  • All patients suitable for surgery.
  • Positive biopsy (Gleason grade >3).
  • Informed consent.

Exclusion Criteria:

  • Patients who do not sign the consent paper for any reason or do not accept the study premises.
  • Patents who want to withdraw for any reason during the study.
  • Patients with contraindications to MRI (pacemaker, claustrophobia etc) and/or surgery.
  • Patients who have undergone a high quality MRI examination of the prostate at another radiological center. In this situation the MR examination is evaluated together with the surgeon but the patient is not included in the study. (In case of a low quality examinations, we will disregard the findings, and include the patient).
  • If the surgeon finds it unacceptable to perform RALP without MRI, because of various reasons (eg. patient demand, too high risk etc) the patient will not be included in the study.
  • If preoperative MRI reveals extensive tumor invasion into adjacent organ (T4) or skeletal metastases (M1), as these cancer stadiums do not benefit from RALP.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01347320

Oslo University Hospital
Oslo, Norway, 0514
Sponsors and Collaborators
Oslo University Hospital
Principal Investigator: Erik Rud, MD Oslo University Hospital, Aker

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Erik Rud, MD, Oslo University Hospital Identifier: NCT01347320     History of Changes
Other Study ID Numbers: OsloUH
First Posted: May 4, 2011    Key Record Dates
Last Update Posted: December 30, 2013
Last Verified: December 2013

Keywords provided by Erik Rud, Oslo University Hospital:
Prostate cancer
preoperative staging
Free surgical margins

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases